N-substituted-3-arylpyrrolidines: Potent and selective ligands at serotonin 1A receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 10, 1999, Pages 1379-1384

  Kyo, Han Ahn ^a   Seok, Jong Lee ^a   Lee, Chang Ho ^b   Hong, Chang Y ^c   Tae, Kyo Park ^c  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Hanyang University College of Medicine   (South Korea)

^c LG Chemical Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; N [(N SACCHARINO)BUTYL]PYRROLIDINE; PYRROLIDINE DERIVATIVE; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENANTIOMER; LIGAND BINDING; NONHUMAN; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; TEMPERATURE; TRANQUILIZING ACTIVITY;

ANIMALS; BEHAVIOR, ANIMAL; LIGANDS; PROTEIN BINDING; PYRROLIDINES; RATS; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGENTS;

EID: 0033577775     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00201-2     Document Type: Article

References (19)

1. Fletcher A, Cliffe IA, Dourish CT. Trends Pharmacol. Sci. 1993;14:441-448.
2. Modica M, Santagati M, Russo F, Parotti L, De Gioia L, Selvaggini C, Salmona M, Mennini T. J. Med. Chem. 1997;40:574-585.
3. Hibert MF, Mir AK, Fozard JR: serotonin (5-HT) receptors. In: Sammes PG, Taylor JB, editors. Comprehensive Medicinal Chemistry, Vol. 3. Oxford: Pergamon Press, 1990:567-600.
4. 50, 3 nM) have been reported as a patent (DE 19615232). We thank the referee who called our attention to this information. Other N-substituted-3-arylpyrrolidine derivatives with different pharmacological behavior have been reported from Abbott laboratories, see: (a) Zelle RE, Hancock AA, Buchner SA, Basha FZ, Tietje K, DeBernardis JF, Meyer MD. Bioorg. Med. Chem. Lett. 1994:4;1319-1322.
5. (b) Basha FZ, DeBernardis JF. Pure & Appl. Chem. 1994:66;2201-2204.
6. (c) Hancock AA, Buckner SA, Giardina WJ, Brune ME, Lee JY, Morse PA, Oheim KW, Stanisic DS, Warner RB, Kerkman DJ, DeBernardis JF. J. Pharmacol. Exp. Ther. 1995:272;1160-1169). Also, a Swedish group has reported different 3-arylpyrrolidine derivatives as potential DA receptor antagonists, see: Sonesson C, Wikström H, Smith MW, Svensson K, Carlsson A, Waters N. Bioorg. Med. Chem. Lett. 1997:7;231-246..
7. (c) Hancock AA, Buckner SA, Giardina WJ, Brune ME, Lee JY, Morse PA, Oheim KW, Stanisic DS, Warner RB, Kerkman DJ, DeBernardis JF. J. Pharmacol. Exp. Ther. 1995:272;1160-1169). Also, a Swedish group has reported different 3-arylpyrrolidine derivatives as potential DA receptor antagonists, see: Sonesson C, Wikström H, Smith MW, Svensson K, Carlsson A, Waters N. Bioorg. Med. Chem. Lett. 1997:7;231-246..
8. Mulzer J, Zuhse R, Schmiechen R. Angew. Chem. Int. Ed. Engl. 1992:31;870-872.
9. Other synthetic methods have been appeared during our study, see: (a) Denmark SE, Marcin LR. J. Org. Chem. 1995:60;3221-3235.
10. (b) De Smaele D, De Kimpe N. J. Chem. Soc. Chem. Commun. 1995:2029-2030.
11. (c) Sonesson C, Larhed M, Nyqvist C, Hallberg A. J. Org. Chem. 1996:61;4756-4763.
12. Gmeiner P. Orecher F, Thomas C, Weber K. Tetrahedron Lett. 1995;36:381-382.
13. 2O, the organic phase was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. Purification of the residue by column chromatography on silica gel (eluent: 10% ethyl acetate in hexanes) afforded the product 3a in 78% yield (685 mg).
14. D +22.7 (c 2.36, EtOH): Tseng CC, Terashima S, Yamada S. Chem. Pharm. Bull. 1977;25:166-170).
15. 3, 75 MHz): δ 170.8, 146.1, 140.1, 136.9, 130.1, 128.8, 128.5, 127.7, 127.4, 126.5, 125.8, 62.7, 60.6, 55.0, 49.2, 43.8, 43.5, 33.8, 26.8, 26.0, 25.0.
16. All the compounds tested were racemic. The binding study for enantiopure (R)-6c and (S)-6c, synthesized in a different approach, indicated that the (S)-isomer was about twice potent than the (R)-isomer: Unpublished results.
17. 2 of rat striatum. Specific binding was measured by subtracting nonspecific binding out of total binding. Nonspecific binding was measured in the presence of specified concentrations of each non-labeled ligands under the same condition as that for measuring total binding.
18. Baldessarini RJ: Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. The Pharmacological Basis of Therapeutics, 9th Ed. New York: McGraw-Hill, 1996:399-430.
19. Martier P, Tissier MH, Adrien J, Puech AJ. Life Sci. 1991;48(26):2505-2511.